Erleada chases leader Xtandi in prostate cancer mkt
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.12.04 12:10:53
가나다라
0
Astellas Xtandi Q3 sales KRW 11.7 billion…53% increase in a year
Janssen's Erleada's quarterly sales reach KRW 4.8 billion in only half a year since reimbursement listing earlier this year
Zytiga sales slow down...Janssen chases Xtandi sales with its follow-on Erleada
▲Pic of Astella
Astellas Pharm Korea ‘Xtandi (enzalutamide)’ took the lead among oral androgen receptor targeted agents (ARTAs) used to treat prostate cancer.In comparison to declining sales of Janssen's ‘Zytiga (Abiraterone),’ sales of Janssen's other prostate cancer drug ‘Erleada (Apalutamide)’ has been rapidly increasing since being released just 6 months ago, chasing Xtandi in the market.
Xtandi's Q3 sales KRW 11.7 billion…top among ARTAs for prostate cancer
The ARTA-type prostate cancer treatment, Xtandi, posted KRW 11.7 billion in sales in Q3. According to IQVIA, a pharmaceutical industry research institute, this represents a 53% increase from the KRW 7.6 billion i
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)